NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Milestone Pharmaceuticals reported financial results and provided a regulatory and corporate update.
Milestone Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the plan to resubmit the NDA for etripamil in PSVT in early Q2 2024 and the extension of the cash runway into 2026 due to recent financing.
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024
- Recent financing extends cash runway into 2026
- FDA reiterated prior guidance on regulatory pathway for AFib-RVR
- End of Phase 2 Meeting expected mid-2024
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
-$868K
Forward guidance
Milestone Pharmaceuticals is focused on resubmitting the NDA for etripamil in PSVT and advancing the drug through potential approval and launch.
Tailwinds
- Resubmitting NDA for etripamil in PSVT in early 2Q 2024.
- Recent financing extends cash runway into 2026.
- Potential future synthetic royalty payment.
- Advancing etripamil through potential approval.
- Advancing etripamil through potential launch in PSVT.
Headwinds
- Risks inherent in biopharmaceutical product development and clinical trials.
- Uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of clinical trials.
- Risk and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data.
- Whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
- Risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+1.7%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+2.2%
Avg return
30 days after
64%
18 / 28 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.5% | -23.2% | — | |
| Q4 2026 | -20.0% | -26.5% | +23.5% | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +1.3% | +6.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.0% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro